Gene may open door for improved keloid, scar treatment
(Henry Ford Health System) Researchers at Henry Ford Hospital in Detroit have identified a gene that may offer a better understanding of how keloid scars develop and potentially open the door to improved treatment for the often painful, itchy and tender scars. The study is the first to demonstrate that an altered AHNAK gene may have a significant biological role in keloid development.
AbstractPurposeVulvovaginal atrophy (VVA) is a commonly reported issue among breast cancer patients, and its aetiology is multifactorial. Treatment is difficult in these women, particularly because the use of oestrogens has traditionally been discouraged. Vaginal laser treatment has been reported to improve symptoms. We aimed to assess the impact on symptoms and sexual function of vaginal laser in women with early breast cancer (EBC).MethodsWe performed a single-arm investigator initiated pilot study of female EBC patients with symptomatic VVA. A total of 3 vaginal laser treatments were administered 4 weeks apart. Qu...
This article discusses techniques for prevention and treatment options for unsightly and hypertrophic scars. PMID: 31587770 [PubMed - in process]
Conclusion: Itch is common in all ACTDs and often under-evaluated and under treated. Pruritus is more common and more severe in DM than in SLE. Treatment of pruritus in ACTDs can be challenging, and sometimes multi-modal therapy is warranted. J Drugs Dermatol. 2019;18(10):995-998. PMID: 31584777 [PubMed - as supplied by publisher]
Conditions: Morphine; Itch Interventions: Drug: Morphine; Drug: Placebo oral tablet; Drug: Histamine; Drug: Cowhage (Mucuna Pruriens); Drug: Codeine; Drug: Compound 48-80 Sponsor: Aalborg University Not yet recruiting
Conclusion: The results of this study lay the foundation for our future research, which includes an international Delphi study among many scar experts, and an international focus group study among scar patients, aiming to elucidate how scar quality must be defined and measured from both professional and patient perspectives.
Abnormal scarring, manifesting as hypertrophic or keloid scars, affects millions of people every year after surgeries, injury, and even as residual from skin disease. These overgrown scars can be painful, itchy, and often disfiguring. Although many treatments for abnormal scars exist, they are often invasive and do not prevent scar recurrence. Spherical nucleic acids (SNAs) are nanoparticle-oligonucleotide conjugates consisting of a nanoparticle core and dense shell of oriented oligonucleotides.
Keloids are exuberant scars which extend beyond the borders of the inciting cutaneous injury, they can be disfiguring, pruritic and/or painful and can cause significant impairment of quality of life (QoL). However, little research has been done to assess the burden of keloids on QoL. Our aim was to assess how severely keloids affect QoL and identify whether symptomatology (pain, itch) was associated with the severity of QoL impairment, using patient-reported measures of symptoms and quality of life.
This article is protected by copyright. All rights reserved. PMID: 30101410 [PubMed - as supplied by publisher]
Conclusions: β-Blockers may be an effective alternative modality for preventing and treating keloids and hypertrophic scars. Large-scale multicenter prospective studies that use histology to diagnose scars and diagnose the postoperative scars at the most suitable period are needed to confirm the effectiveness of blockers for abnormal scars. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
This study evaluated the association of keloid disease with health-related quality of life (HRQL) and identified indicators of burden using a cross-sectional survey study, with 1 disease-specific HRQL measure (Skindex-29) and 2 generic HRQL measures (SF-36 and EQ-5D-5L). A total of 106 keloid patients with no other skin diseases participated in the study. Having keloid disease was associated with a considerable impairment of emotional wellbeing, with most impairment on the emotional and mental HRQL. Pain and itch were the strongest indicators of HRQL impairment in keloid patients. Having painful or itchy keloids was relate...